Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

'We Know We Will Emerge Stronger In The U.S.,' Says Ranbaxy CEO Atul Sobti: An Interview With PharmAsia News (Part 1 of 2)

This article was originally published in The Pink Sheet Daily

Executive Summary

Indian generic firm's new chief executive talks about adapting to majority ownership by Daiichi Sankyo and about being under the FDA magnifying glass.

You may also be interested in...



As Ranbaxy Founders Exit, Daiichi Sankyo Assumes Complete Control; New Management Expects To Resolve U.S. FDA Issue

MUMBAI - Less than one year after acquiring a 64 percent equity stake in India's Ranbaxy for $4.6 billion, Japanese drug maker Daiichi Sankyo has taken complete control of the company's management after reaching an "amicable" agreement on the exit of Malvinder Singh, the grandson of Ranbaxy's founder, and two other directors: Sunil Godhwani and Balinder Dhillon

Daiichi Sankyo Reports First Annual Loss Since 2005 Merger; Plans To Improve Ranbaxy Management

Daiichi Sankyo announced May 12 its first annual loss for fiscal year 2008 since its 2005 merger with Sankyo Pharmaceutical. The third-largest Japanese drug maker announced a net loss of ¥335.8 billion, compared to ¥97.6 billion in net profit for FY2007. The huge loss is a direct result of ¥351.3 billion in write offs for Daiichi Sankyo's Indian subsidiary Ranbaxy Laboratories, which has been crippled by an export ban and investigation by U.S. FDA

Cipla’s Manufacturing Units In India Under U.S. FDA Lens; Inspectional Observations Issued

MUMBAI - U.S. FDA conducted inspections of three manufacturing sites belonging to Indian drug maker Cipla and issued nine to 10 "Inspectional Observations" on various manufacturing issues. The manufacturing sites inspected by FDA are in Goa, Kurkumbh and Bangalore

Related Content

Topics

UsernamePublicRestriction

Register

LL016789

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel